Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer gene therapies - Chemomab Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: cancer gene therapies - Chemomab Therapeutics

Alternative Names: BC-820; BC-821; BC-822; H19-DTA+TNF; IGF2-DTA

Latest Information Update: 14 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCancell Therapeutics
  • Developer Chemomab Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 14 Jun 2021 Chemomab therapeutics has patent protection for cancer-specific TNF-α and DTA mutual expression vector, H19 targeted siRNA for cancer and H19 targeted siRNA for rheumatoid arthritis in USA, before June 2021
  • 14 Jun 2021 Chemomab therapeutics has pending patent protection for composition of matter and method of use for BC 821 in USA, before June 2021
  • 16 Mar 2021 Anchiano Therapeutics has been merged with Chemomab and changed its name to Chemomab Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top